Latest Imatinib Stories
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival.
Drug resistance is a serious problem for cancer patients—over time, a therapy that was once providing some benefit simply stops working. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) recently discovered how cancer cells develop resistance to a drug called MLN4924.
A 21,626-person study published today in the Journal of Clinical Oncology found that the five-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL), the most common childhood cancer, improved from 83.7 percent in those diagnosed during the years 1990-1994, to 90.4 percent for those diagnosed in the years 2000-2005.
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.
By reformulating the common cancer drug imatinib (Gleevec®), researchers have eliminated morphine tolerance in rats – an important step toward improving the effectiveness of chronic pain management in patients.
Big Mountain Drugs, a licensed Canadian online pharmacy, is responding to the recent medication shortage by offering $25.00 off any cancer therapy order over $100.00.
About one in five or six cases of adult leukemia in Western populations relates to so-called chronic myeloid leukemia, or CML.